Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients

Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients

Objectives: This 109-week, nonrandomized, observational study of mucopolysaccharidosis II (MPS II) patients already enrolled in the Hunter Outcome Survey (HOS) (NCT00882921), assessed the long-term immunogenicity of idursulfase, and examined the effect of idursulfase-specific antibody generation on...

Full description

Bibliographic Details
Main Authors: R. Giugliani, P. Harmatz, S.A. Jones, N.J. Mendelsohn, A. Vellodi, Y. Qiu, C.J. Hendriksz, S. Vijayaraghavan, D.A.H. Whiteman, A. Pano
Format: Article
Language:English
Published: Elsevier 2017-09-01
Series:Molecular Genetics and Metabolism Reports
Subjects:
Neutralizing antibodies
Idursulfase
Hunter syndrome
Enzyme replacement therapy
Cognitive impairment
Immunogenicity
Glycosaminoglycans
Online Access:http://www.sciencedirect.com/science/article/pii/S2214426916301173

Internet

http://www.sciencedirect.com/science/article/pii/S2214426916301173

Similar Items